BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Akeso Secures China IND Clearance For First In Class Trispecific Antibody AK150 Targeting Solid Tumours

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...

March 17, 2026 | News

Unixell Biotech Secures US FDA IND Clearance For iPSC Derived Epilepsy Cell Therapy

Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational N...

March 16, 2026 | News

Biophytis And LynxKite Expand AI Drug Discovery Alliance To Advance Next Generation Longevity Therapies

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will...

March 16, 2026 | News

Meiji Seika Pharma Initiates Phase I Trial Of ME3241 PD 1 Agonist Antibody For Autoimmune Diseases

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced that it has in...

March 12, 2026 | News

Curatis Partners With Neupharma To Advance Corticorelin Development For Brain Tumour Related Edema In Japan

Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developi...

March 12, 2026 | News

Ascletis Reports Positive Phase II Results For Monthly ASC30 Injection In Obesity Treatment

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of ...

March 11, 2026 | News

China Clears IND For Harbour BioMed And Kelun Biotech Bispecific Antibody For Atopic Dermatitis

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology an...

March 10, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Insilico Medicine AI Discovered CKD Anemia Drug ISM4808 Enters Phase I Clinical Trial

Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced th...

March 09, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Thermo Fisher Opens Advanced Distribution And Labelling Centre In Uppsala To Strengthen Global Immunodiagnostics Supply

Thermo Fisher Scientific Inc., the world leader in serving science, announced the opening of a new 8,000-square-meter distribution and labeling center supp...

March 05, 2026 | News

Senhwa Biosciences And CellType Partner To Advance AI Driven Development Of CX 4945 Cancer Therapy

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and inf...

March 05, 2026 | News

Antengene Grants UCB Global Rights To Develop And Commercialise ATG 201 Bispecific T Cell Engager

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, t...

March 05, 2026 | News

XellSmart Secures Fourth Dual US And China Regulatory Clearance For iPSC Derived Cell Therapy In Multiple System Atrophy

XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for P...

March 04, 2026 | News

Stay Connected